Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryDec032015	Fate Therapeutics to Present at Oppenheimer & Co. 26th Annual Healthcare Conference SAN DIEGO , Dec. 3, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All »	View HTML Fate Therapeutics to Present at Oppenheimer & Co. 26th Annual Healthcare Conference 16.6 KB
Toggle SummaryNov252014	Fate Therapeutics to Present at Piper Jaffray 26th Annual Healthcare Conference SAN DIEGO, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, Read All »	View HTML Fate Therapeutics to Present at Piper Jaffray 26th Annual Healthcare Conference 10.8 KB
Toggle SummarySep032014	Fate Therapeutics to Present at Rodman & Renshaw 16th Annual Global Investment Conference SAN DIEGO, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer Read All »	View HTML Fate Therapeutics to Present at Rodman & Renshaw 16th Annual Global Investment Conference 10.1 KB
Toggle SummarySep022015	Fate Therapeutics to Present at September Investor Conferences SAN DIEGO, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the development of programmed cellular immunotherapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President Read All »	View HTML Fate Therapeutics to Present at September Investor Conferences 10.6 KB
Toggle SummaryFeb222021	Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference SAN DIEGO , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will present at Read All »	View HTML
Toggle SummaryFeb052015	Fate Therapeutics to Present at the 2015 Leerink Global Healthcare Conference SAN DIEGO, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Read All »	View HTML Fate Therapeutics to Present at the 2015 Leerink Global Healthcare Conference 10.5 KB
Toggle SummaryAug102016	Fate Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference SAN DIEGO, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will Read All »	View HTML Fate Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference 11.1 KB
Toggle SummaryNov212017	Fate Therapeutics to Present at the 2017 Piper Jaffray Healthcare Conference SAN DIEGO, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Read All »	View HTML Fate Therapeutics to Present at the 2017 Piper Jaffray Healthcare Conference 12.6 KB
Toggle SummaryAug092017	Fate Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference SAN DIEGO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Read All »	View HTML Fate Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference 11.8 KB
Toggle SummaryAug072018	Fate Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference SAN DIEGO , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.